Torsade de Pointes after Administration of Droperidol for Nausea andVomiting

References

• Available at: http://www.fda.gov/medwatch/safety/2001/safety01.htm#inapsi MedWatch 2001 Safety Information Summaries: Inapsine (droperidol) [cited February 1, 2008]. Accessed July 1, 2008
   Google Scholar
• Martel M, Miner J, Fringer R, et al. Discontinuation of droperidol for the control of acutely agitated out-of-hospital patients. Prehosp Emerg Care 2005; 9: 44–8
   PubMedGoogle Scholar
• Jacoby J L, Fulton J, Cesta M, Heller M. After the black box warning: dramatic changes in ED use of droperidol. Am J Emerg Med 2005; 23: 196
   PubMedGoogle Scholar
• McEvoy G K. Anxiolytics, sedatives, andhypnotics. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD 2007
   Google Scholar
• Chase P, Biros M. A retrospective review of the use andsafety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med 2002; 9: 1402–10
   PubMed Web of Science ®Google Scholar
• Rosen C L, Ratliff A F, Wolfe R E, Branney S W, Roe E J, Pons P T. The efficacy of intravenous droperidol in the prehospital setting. J Emerg Med 1997; 15: 13–7
   PubMedGoogle Scholar
• Hick J, Mahoney B, Lappe M. Prehospital sedation with intramuscular droperidol: a one-year pilot. Prehosp Emerg Care 2001; 5: 391–4
   PubMedGoogle Scholar
• Habib A, Gan T. The use of droperidol before andafter the Food andDrug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia. J Clin Anesth 2008; 20(1)35–9
   PubMed Web of Science ®Google Scholar
• Apfel C C, Korttila K, Abdalla M, et al. IMPACT Investigators. A factorial trial of six interventions for prevention of postoperative nausea andvomiting. N Engl J Med 2004; 350: 2441–51
   PubMed Web of Science ®Google Scholar
• Henzi I, Sonderegger J, Tramer M R. Efficacy, dose-response, andadverse effects of droperidol for prevention of postoperative nausea andvomiting. Can J Anesth 2000; 47: 537–51
   PubMed Web of Science ®Google Scholar
• Gan T J, Meyer T A, Apfel C C, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea andvomiting. Anesth Analg 2007; 105: 1615–28
   PubMed Web of Science ®Google Scholar
• Weichenthal L, Soliz T. The incidence andtreatment of prehospital motion sickness. Prehosp Emerg Care 2003; 7: 474–6
   PubMedGoogle Scholar
• Roden D. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013–22
   PubMed Web of Science ®Google Scholar
• Khan I A. Clinical andtherapeutic aspects of congenital andacquired long QT syndrome. Am J Med 2002; 112(1)58–66
   PubMedGoogle Scholar
• Al-Khatib S M, LaPointe N MA, Kramer J M, Califf R M. What clinicians should know about the QT interval. JAMA 2003; 289: 2120–27
   PubMed Web of Science ®Google Scholar
• Resnick M, Burton B T. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychopharmacol 1984; 45(7)298–9
   Google Scholar
• Sharma N D, Rosman H S, Padhi D, Tisdale J E. Torsade de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81: 238–44
   PubMed Web of Science ®Google Scholar
• Warden C, Moreno R, Daya M. Prospective evaluation of ondansetron for undifferentiated nausea andvomiting in the prehospital setting. Prehosp Emerg Care 2008; 12: 87–91
   PubMed Web of Science ®Google Scholar
• Horowitz B, Bizovi K, Moreno R. Droperidol—behind the black box warning. Acad Emerg Med 2002; 9: 615–8
   PubMed Web of Science ®Google Scholar
• Kao L W, Kirk M A, Evers S J, Rosenfeld S. Droperidol, QT prolongation, andsudden death: what is the evidence?. Ann Emerg Med 2003; 41: 546–58
   PubMed Web of Science ®Google Scholar
• Habib A, Gan T. Food andDrug Administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003; 96: 1377–9
   PubMed Web of Science ®Google Scholar
• Nuttall G A, Eckerman K M, Jacob K A, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation andtorsade de pointes in the general surgical population?. Anesthesiology 2007; 107: 531–6
   PubMed Web of Science ®Google Scholar
• Lischke V, Behne M, Doelken P, Scheldt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994; 79: 983–6
   PubMed Web of Science ®Google Scholar
• White P F, Song D, Abrao J, Klein K W, Navarette B. Effect of low-dose droperidol on the QT interval during andafter general anesthesia: A placebo-controlled study. Anesthesiology 2005; 102: 1101–5
   PubMed Web of Science ®Google Scholar
• Curry S, DeVane C, Wolfe M. Cimetidine interaction with amitriptyline. Eur J Clin Pharmacol 1985; 29: 429–33
   PubMedGoogle Scholar
• Schneider L S, Small G W, Hamilton S H, Bystritsky A, Nemeroff C B, Meyers B S. Estrogen replacement andresponse to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry 1997; 5: 97–106
   PubMed Web of Science ®Google Scholar
• Chan M T, Choi K C, Gin T, et al. The additive interactions between ondansetron anddroperidol for preventing postoperative nausea andvomiting. Anesth Analg 2006; 103: 1155–62
   PubMed Web of Science ®Google Scholar
• Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea andvomiting treatment by droperidol or ondansetron. Anesthesiology 2005; 102: 1094–100
   PubMed Web of Science ®Google Scholar
• Makkar R R, Fromm B S, Steinman R T, Meissner M D, Lehmann M H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590–7
   PubMed Web of Science ®Google Scholar
• FDA approves first generic ondansetron injection. US Food andDrug Administration, Available at: http://www.fda.gov/bbs/topics/news/2006/new01513.html Accessed January 22, 2009
   Google Scholar